PF-Atlas › Clinical Trials › NCT00532233
SD, IL-13 Production Rate in IPF
QAX576 · Phase 2
Registry ID
NCT00532233
Phase
Phase 2
Status
Completed
Drug / intervention
QAX576
Sponsor
Novartis Pharmaceuticals
Start
2007-09
Enrollment
52
Locations
6
About this trial
The purpose of this study is to investigate how QAX576 affects levels of interleukin 13 (IL-13) in patients with idiopathic pulmonary fibrosis (IPF).
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT00532233 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.